Enrique Ocio, MD, PhD, obtained his medical degree from the University of Salamanca, Salamanca, Spain, in 1999, where he also specialized in hematology. Between 2005-2006, Dr Ocio was a post-doctoral researcher at the Dana Farber Cancer Institute, Boston, MA, working on the development of novel therapies for multiple myeloma. Dr Ocio was also previously an Associate Professor of Medicine at the University of Salamanca, Salamanca, Spain.
Dr Ocio is currently the Head of Hematology at the Marqués de Valdecilla University Hospital, Santander, Spain, where he coordinates the Clinical Trials Unit of the department and the Phase I Trials Unit.
Speaking on the development of new clinical trials and drugs for multiple myeloma
Dr Ocio focuses on unravelling the complex biology underlying the development and progression of multiple myeloma as well as developing novel treatments. Dr Ocio is Principal Investigator for several trials, namely a Phase I/II trial exploring filanesib in combination with pomalidomide and dexamethasone for relapsed/refractory multiple myeloma (NCT02384083) and, more recently, the Phase I DREAMM 9 trial (NCT04091126) investigating belantamab mafodotin plus standard of care in newly diagnosed multiple myeloma.